DLA Piper advised Axsome Therapeutics on the offering.Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system…
Axsome Therapeutics’ US$225 Million Shares Public Offering
